Four months after Avidity’s $11.4 billion buyout, Atrium debuted with $270 million in cash and plans to pick up its ...

With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology advances.

Atrium Therapeutics, Inc. (Nasdaq: RNA) launched today as a newly independent, publicly traded company dedicated to delivering RNA therapeutics directly to the heart to transform care for people ...

Add Yahoo as a preferred source to see more of our stories on Google. Researchers report a new RNA drug called TY1 improves heart healing in animals by repairing DNA and calming immune cells after ...

Data demonstrating superior selectivity, safety and pharmacokinetics of RGT-0474060 were presented at the 21st Annual Huntington’s Disease ...

Add Yahoo as a preferred source to see more of our stories on Google. Depiction of man experiencing a heart attack Image by Canva An experimental synthetic RNA drug has shown promise in repairing ...

Despite the availability of effective antihypertensive therapies, global blood pressure control rates remain unacceptably low. Contributing factors, such as low treatment adherence, therapeutic ...

Discover how circular RNA technology enhances gene expression by up to 50-fold in eye treatments, surpassing traditional ...

DENVER -- The two-drug combination of doravirine and islatravir was as efficacious as the three-drug regimen of bictegravir, ...

New research shows that lipid nanoparticles used in mRNA vaccines may deliver RNA more effectively when their structure is disorganised.

(a) Success rate, timeline, and cost (in billions) of traditional drug development versus RNA drug development, along with a description of the evolutionary progress of the latter. (b) The future ...

In just the past few years, researchers have found a way to use a naturally occurring bacterial system known as CRISPR/Cas9 to inactivate or correct specific genes in any organism. CRISPR/Cas9 gene ...